Daily Respiratory Research Analysis
Analyzed 61 papers and selected 3 impactful papers.
Summary
Three impactful respiratory papers span translational vaccinology, tumor biology, and precision biologics. A single-cycle VSV-vectored HA/NA influenza vaccine in pigs prevented shedding of an antigen-drifted H1N1 strain, a Cell Reports study uncovered a neural-STMN2–β-alanine axis driving perineural invasion in small cell lung cancer, and pooled Phase III data showed twice-yearly depemokimab confers early, sustained exacerbation reduction in type 2 asthma.
Research Themes
- Cross-protective respiratory vaccination to block transmission
- Neuro–tumor metabolic crosstalk driving lung cancer invasion
- Ultra-long-acting biologics enabling adherence and precision asthma control
Selected Articles
1. Non-propagating RNA virus-vectored HA/NA vaccine prevents shedding of antigen-drifted H1N1 influenza virus in pigs.
A single-cycle VSV vector expressing both HA and NA elicited robust neutralizing and anti-neuraminidase responses in pigs and completely prevented shedding after challenge with a drifted H1N1 strain. Induced N1 antibodies also inhibited avian N1 and suppressed bovine H5N1 replication in vitro, suggesting broad cross-protection.
Impact: Demonstrates transmission-blocking potential against antigen-drifted influenza using a scalable vector, directly addressing vaccine mismatch. The porcine model strengthens translational relevance to human upper airway physiology.
Clinical Implications: If confirmed in humans, this platform could reduce community transmission by eliminating shedding and mitigate mismatch years. It supports development of prime-boost strategies integrating HA and NA to broaden protection.
Key Findings
- Single intramuscular immunization induced high H1N1 neutralization titers and strong N1-sialidase inhibition.
- Boosting (homologous VSV or heterologous LAIV) enhanced inhibition against drifted A/Victoria/2570/2019 H1N1.
- Vaccinated pigs had no detectable virus shedding after nasal challenge with a drifted HA/NA reassortant; controls shed virus.
- N1-specific antibodies inhibited avian N1 and suppressed bovine-derived H5N1 replication in vitro.
Methodological Strengths
- Translationally relevant porcine model with functional endpoint of viral shedding.
- Prime-boost comparisons (homologous VSV vs heterologous LAIV) and cross-clade functional assays including avian N1 and H5N1.
Limitations
- Preclinical animal study; human immunogenicity, safety, and durability remain untested.
- Exact sample size and duration of post-challenge monitoring not specified in the abstract; vector immunity and manufacturing scalability require evaluation.
Future Directions: Proceed to phase 1 trials assessing safety, mucosal immunity, and shedding, evaluate durability and breadth across drifted strains, and assess potential to limit zoonotic H5Nx transmission.
Seasonal influenza viruses evade immunity through antigenic drift, enabling escape from inhibitory antibodies targeting hemagglutinin (HA) and neuraminidase (NA). In this study, we evaluated a non-propagating vesicular stomatitis virus (VSV) vector encoding HA and NA antigens of A/Hamburg/4/2009 (H1N1) in a porcine animal model to assess induction of cross-reactive immunity. A single intramuscular immunization elicited high titers of H1N1-neutralizing antibodies and potent N1-sialidase inhibition. A boost with the same single-cycle VSV-vectored H1/N1 antigens or with a live-attenuated influenza vaccine (LAIV) enhanced inhibitory activity against the antigen-drifted A/Victoria/2570/2019 (H1N1) strain. Vaccination induced N1-specific antibodies that also inhibited avian N1 sialidase and suppressed replication of a bovine-derived H5N1 virus in vitro. Following nasal challenge with a 6:2 reassortant virus encoding drifted HA and NA antigens, vaccinated pigs showed no detectable virus shedding, whereas control animals shed infectious virus. Homologous prime-boost vaccination with the VSV-vectored H1/N1 antigens conferred protection comparable to the heterologous VSV/LAIV regimen in the upper respiratory tract. These findings demonstrate that a single-cycle VSV vector encoding both HA and NA induces cross-protective immunity against antigen-drifted influenza viruses, reduces the risk of vaccine mismatch, and may limit infection by zoonotic H5N1 viruses.
2. Regulation of neuronal invasion of small cell lung cancer by STMN2/β-alanine-controlled metabolic reprogramming.
This study identifies a neural-STMN2–β-alanine axis that metabolically reprograms SCLC to promote perineural invasion. STMN2 knockdown reduced neural invasion in vivo, and β-alanine supplementation reversed this, defining a druggable metabolic vulnerability.
Impact: Reveals a mechanistic link between neural microenvironment cues and tumor metabolic reprogramming that drives invasion, opening avenues for metabolism-targeted anti-invasion therapies in SCLC.
Clinical Implications: Targeting STMN2 or β-alanine metabolism could reduce perineural invasion and associated morbidity in SCLC; PNI may also serve as a stratification biomarker for trials testing metabolic inhibitors.
Key Findings
- Perineural invasion (PNI) is an independent adverse prognostic factor in a surgical SCLC cohort.
- Neural microenvironment upregulates STMN2, which activates the β-alanine metabolic pathway and increases intracellular β-alanine.
- STMN2 knockdown suppresses neural invasion in vivo; β-alanine supplementation reverses the effect.
Methodological Strengths
- Integration of clinical prognostic analysis with mechanistic in vitro and in vivo validation.
- Rescue experiments (β-alanine supplementation) strengthen causal inference for the STMN2–β-alanine axis.
Limitations
- Generalizability to non-surgical, metastatic, or treated SCLC populations is unclear.
- Therapeutic targeting feasibility and on-target toxicity of modulating β-alanine metabolism remain to be established in vivo in humans.
Future Directions: Validate STMN2/β-alanine signatures in larger SCLC cohorts, develop inhibitors or metabolic modulators, and test anti-invasion efficacy and safety in preclinical and early-phase clinical trials.
Small cell lung cancer (SCLC) exhibits a high incidence of perineural invasion (PNI), a clinical feature associated with poor prognosis. Here, we establish PNI as an independent adverse prognostic factor in a surgical SCLC cohort. We further show that the neural microenvironment upregulates stathmin-2 (STMN2) in SCLC cells. STMN2, in a concentration-dependent manner, activates the β-alanine metabolic pathway, leading to intracellular β-alanine accumulation, which enhances tumor cell migration and invasion. In vivo, STMN2 knockdown suppresses neural invasion, an effect reversible upon β-alanine supplementation. This work defines a neural-STMN2-β-alanine-invasion axis that drives PNI in SCLC, providing mechanistic insights and highlighting a promising metabolic vulnerability for therapeutic intervention.
3. Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.
Twice-yearly depemokimab rapidly reduced exacerbation risk from week 4 and sustained benefits through 52 weeks, with pronounced effects in patients with shorter disease duration, comorbid CRSwNP, and medium-dose ICS. Patient-reported outcomes and rescue medication use also improved.
Impact: Demonstrates early-onset, durable efficacy of an ultra-long-acting IL-5 pathway biologic, addressing adherence and access challenges by enabling semiannual dosing while maintaining robust control of type 2 inflammation.
Clinical Implications: Supports incorporating depemokimab as a semiannual option for type 2 asthma, particularly in patients with CRSwNP or shorter disease duration, potentially improving adherence and outcomes without increasing visit burden.
Key Findings
- Depemokimab reduced the hazard of first exacerbation over 52 weeks by 46% (HR 0.54 [95% CI 0.43–0.69]) with effects evident from Week 4.
- Exacerbation reductions were greatest in patients with disease duration <10 years, comorbid CRSwNP, and medium-dose ICS baseline.
- Improvements were observed in SGRQ, ACQ-5, ANSD/ADSD scores, and rescue medication use across dosing periods.
Methodological Strengths
- Pooled analysis of two Phase III randomized, placebo-controlled trials with pre-specified endpoints.
- Time-to-event analysis and consistent efficacy across two 26-week dosing intervals.
Limitations
- Subgroup findings were post hoc and hypothesis-generating.
- Follow-up limited to 52 weeks; generalizability to high-dose ICS users and type 2-low phenotypes is uncertain.
Future Directions: Head-to-head comparisons with other biologics, longer-term safety and durability studies, and biomarker-driven enrichment in populations with CRSwNP and early disease.
BACKGROUND: Depemokimab, the first ultra-long-acting biologic, with enhanced IL-5 binding affinity, high inhibition potency, and extended half-life, enables twice-yearly dosing in patients with asthma. In Phase III SWIFT-1/-2 trials, depemokimab significantly reduced the annualized exacerbation rate by 54% versus placebo with sustained suppression of inflammation assessed by blood eosinophil count in type 2 asthma. OBJECTIVE: To evaluate onset and duration of depemokimab efficacy across each 26-week dosing period in the pooled SWIFT-1/-2 population and identify patient characteristics associated with enhanced clinical response. METHODS: Methods: Patients with type 2 asthma, independent of ACQ-5 status, were randomized 2:1 to receive depemokimab 100 mg subcutaneously or placebo every 26 weeks for 52 weeks. Pre-specified endpoints included time to first exacerbation, SGRQ/ACQ-5 scores, ANSD/ADSD weekly scores, and rescue medication use over time. Post hoc subgroup analyses by baseline characteristics were conducted. RESULTS: Depemokimab reduced the probability of first exacerbation over 52 weeks versus placebo by 46% (HR [95% CI]: 0.54 [0.43, 0.69]), with effects from Week 4 sustained across both dosing periods. Annualized exacerbation rate reductions were most pronounced in patients with asthma disease duration <10 years, comorbid CRSwNP, and medium-dose ICS at baseline. Across each dosing period, depemokimab also improved SGRQ/ACQ-5/ANSD/ADSD scores, particularly in patients with baseline ACQ-5 scores ≥1.5, with sustained improvements in rescue medication. CONCLUSION: Early and sustained efficacy with depemokimab was observed across 26-week dosing periods in type 2 asthma, with enhanced benefits in patients with shorter disease duration who had not progressed to high-dose ICS. GOV IDENTIFIER: NCT04719832/NCT04718103.